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a b s t r a c t
We report a patient with non-ischemic dilated cardiomyopathy and low left ventricular
systolic function (28%) presenting with an electrical storm originated in epicardial scar and
ablated by radiofrequency. This case report suggests that a strategy of epicardial catheter
ablation is reasonable for the patient presenting with electrical storm related to structural
disease with a low left ventricular ejection fraction.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Epicardial1. IntroductionPatientswith non-ischemic dilated cardiomyopathy (DCM) are
at high risk for sudden cardiac death due to sustained
ventricular tachycardia (VT) or ventricular ﬁbrillation (VF).1
Randomized trials have proven the beneﬁt of an implantable
cardioverter-deﬁbrillator (ICD) as comparedwith anti-arrhyth-
mic drug therapy, and current guidelines recommend ICD
therapy in both primary and secondary prevention.2–7 Al-
though ICDs improve overall survival, they do not eliminate
the arrythmogenic substrate. Despite the presence of an ICD,
the occurrence of a ventricular arrhythmia storm (≥3 hemo-
dynamically destabilizing VTs in a 24-h period or the detection* Corresponding author.
E-mail address: carmine.pizzi@unibo.it (C. Pizzi).
http://dx.doi.org/10.1016/j.ihj.2016.01.010
0019-4832/# 2016 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).of ≥3 VTs in a 24-h period in ICD patients) may still lead to
elevated mortality.8 According to the above-mentioned deﬁ-
nition, the incidence of electrical storm (ES) ranges from 4%,
over a 20.6-month period of follow-up in those studies in
which ICD implantation was carried out for primary preven-
tion, to 20% over a 31-month period of follow-up in secondary
prevention ICD recipients.8
InpatientsexperiencingES, thekey intervention is reduction
of the sympathetic tone using beta-blockers, frequently
combined with benzodiazepines; amiodarone intravenous
infusion is also recommended while class I antiarrhythmic
drugs are usually unsuccessful.8 The non-pharmacological
therapeutic option for the recurrence of VT or VF is transcath-
eter ablation of ventricular arrhythmogenic foci.9–12B.V. This is an open access article under the CC BY-NC-ND license
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lished role in the treatment of recurrent VT, its therapeutic role
in patients with ES has been investigated only in selected
populations with implanted ICDs. The current guidelines
suggest that VT ablation intervention be used as an adjunctive
therapy to ICD while radiofrequency ablation strategy alone
has never been assessed in patients with structural heart
disease and a low ejection fraction.
2. Case reportFig. 1 – Electroanatomical mapping. Left ventricular
posterior views of epicardial mapping (A) and endocardial/
epircardial map (B). The earliest epicardial activation site
during ventricular tachycardia (A, marked by a white
arrow) shows the site where VT has been interrupted, and
brown tags (A and C) indicate the ablation site on the LAVA
potentials. A white circle (C) indicates voltage mapping
during sinus rhythm (C) with isolated delayed potential
around the ablation area.A 55-year-old man was admitted to the hospital due to a
syncope episode preceded by palpitation. The patient had no
cardiovascular risk factors, no familial history of suddencardiac
death, and no previous history of cardiovascular disorders,
includingsyncopeorpalpitationepisodes.During transport, the
patient developed VT with hypotension and was deﬁbrillated
twice with 200 J from a biphasic deﬁbrillator with standard
anterior and lateral placement (one pad right parasternal and
the second at the cardiac apex) obtaining temporary recovery of
sinus rhythmwith subsequent numerous subentrant episodes
of VT. An IV infusion of amiodarone was immediately started
and another 4 DC shocks were administered. While in the
coronary care unit, by utilizing a conventional 12 lead surface
electrocardiogram (ECG), sustained, wide complex tachycardia
witha rateof 234beatsperminutewith right bundlebrunchand
right-axis deviation morphology, and a pseudodelta wave in
precordial leads were recorded. The tachycardia morphology
was consistentwith thediagnosis ofVToriginating fromthe left
ventricle. The intravenous infusion of amiodarone, lidocaine,
beta blockers, and magnesium sulfate was carried out with no
resolution of the arrhythmia. After deep sedation and oro-
tracheal intubation, sinus rhythm was restored by means of
electrical cardioversion. Written informed consent for the
cardiac catheterization and eventual electrophysiological study
was obtained from the family of the patient. The patient
underwent urgent cardiac catheterization, and coronary angio-
gram documented normal coronary vessels and diffuse left
ventricular (LV) hypokinesia (left ventricular ejection fraction
(LVEF) = 28%). The patient was referred for emergency
electrophysiological study. Endocardial mapping did not iden-
tify any low-voltage areas suggestive of anarrhythmia focus. As
the ECG-guided morphological analysis of the arrhythmia was
coherent with an epicardial origin (pseudodelta wave) of the
arrhythmia, a subxiphoid approach was undertaken to achieve
pericardial access as described by Sosa et al.13 Epicardial LV
mapping during sinus rhythm revealed a 1.6 cm2 scar at the
posterolateral region of the basal segment of the LV epicardium
withavoltageof0.6 mV.AfterVTwas induced (QRSmorphology
is identical to spontaneous ventricular arrhythmia), this
isolated delayed potential became mid-diastolic and pre-
systolic (180 ms before QRS complexes) (Fig. 1). One pulse
radiofrequency current at this site interrupted VT after 4.5 s
(maximumpower,45W;maximumtemperature, 42 8C). Several
additional radiofrequency applications were placed in close
proximity adjacent to this site on local abnormal ventricular
activities (LAVA) potentials (Fig. 2). Coronary angiography was
not performed before radiofrequency delivery because there
was low possibility of damage of main coronary artery vessel.After the ablations were completed, VT could no longer be
provoked.
The ﬁndings are consistent with a small, epicardial
arrhythmogenetic scar area, possibly related to idiopathic
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Fig. 2 – A twelve-lead ECG during ventricular tachycardia. Note the right bundle-branch morphology of the QRS complex (A).
Findings during epicardial mapping during ventricular tachycardia show the presence of presystolic or mid-diastolic
fragmentation (B). Panel (C) shows that the isolated potential in the epicardium occurs approximately 180 ms before the QRS
complex during VT. Ablation at the epicardial site terminates ventricular tachycardia. In this area, during sinus rhythm it is
possible to observe local abnormal ventricular activities (LAVA) potentials (white arrows). LAVA was defined as electrograms
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ﬂammatory and non-inﬂammatory causes of idiopathic
cardiomyopathy. Since we did not perform cardiac magnetic
resonance, we cannot exclude a priori areas of myocardial
inﬂammation or ﬁbrosis near the site of epicardial ablation.
During follow-up, no further ventricular arrhythmias were
registered over a period of 30 days after ablation. Echocardi-
ography showed severe LV systolic dysfunction with a LV
ejection fraction of 28%.A dual chamber ICDwas implanted for
secondary prevention. At a 24-month follow-up, no further
episodes of VT were recorded. No antiarrhythmic therapy was
administered following the ablation.
3. DiscussionThis case report suggests that a strategy of epicardial catheter
ablation is reasonable for a patient presenting with ES related
to structural disease having a low LVEF (LVEF = 28%).
Randomized controlled trials support the use of ICDs for the
secondary prevention of sudden cardiac death. In patients
with a history of cardiac arrest, an ICD is associated with
clinically and statistically signiﬁcant reductions in sudden
death and total mortality as compared with antiarrhythmic
drug therapy.1
Catheter ablation (CA) has a well-established role in
managing recurrent VT in order to reduce shocks in patients
with ICDs. Many studies have demonstrated that, after CA, the
frequency of VT was reduced by 50–67% at a 6-month follow-
up. Della Bella et al. have demonstrated that the elevated
success rate of CA is associated with a lower arrhythmia
recurrence rate, also due to the systematic implementation of
an ablation strategy, which focused on endocardial-epicardial
substrate modiﬁcation, independent of VT inducibility and
tolerance. CA also improved the survival rate by 18–25% in a
1-year follow-up period.12
Transthoracic epicardial radiofrequency has been demon-
strated to be a safe, feasible, and effective alternative in
patients undergoing unsuccessful endocardial ablation.13
Generally, an epicardial approach was performed in 17–19%
of VT ablation procedures ranging from 6% in normal hearts to
16% for ischemic cardiomyopathy, 35% for DCM, and 41% for
arrhythmogenic right ventricular cardiomyopathy.14 However,
there are no reports in the literature regarding this procedure
in patients before ICD implantation. Recently, Maury et al.
reported that CA with a deferral of ICD implantation is
reasonable for a patient presenting with well-tolerated
sustained monomorphic VT related to structural disease
having an LVEF > 30%.15 However, this ablation strategy has
not been reported in patients with hemodynamically non-
tolerated VTs and with severe altered left ventricular function
as in our case report. We decided to implant an ICD after CA
because a poor left ventricular ejection fraction and ES arefrom poorly coupled surviving myocardial fibers with the followi
distinct from the far-field ventricular electrogram; (2) occurring a
ventricular electrogram during sinus rhythm; and (3) sometimes
separated by very low-amplitude signals or an isoelectric interv
reduction in arrhythmia-free survival.independent predictors of VT recurrence, even if our patient
had no arrhythmias in a 24-month follow up. Patients with VT
ablation are more likely to remain at risk of sudden death and
an ICD is usually warranted before hospital discharge.1
4. ConclusionTo our knowledge, this is the ﬁrst case reporting the efﬁcacy of
urgent VT ablation in a patient presenting with hemodynami-
cally non-tolerated ES. Furthermore, we considered multiple
factors in making our decision regarding this epicardial
approach; this included ECG analysis of the clinical VT for
features suggesting an epicardial source, history of previous
failed endocardial ablation, and the presence of ES.
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